Recent Advances in the Development of Beta-Lactamase Inhibitors
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Mechanism and Evolution of Antibiotic Resistance".
Deadline for manuscript submissions: closed (30 October 2022) | Viewed by 2690
Special Issue Editors
Interests: X-ray crystallography; structural biology; β-lactamases; antibiotic resistance; bacterial thymidylate synthase; human thymidylate synthase; pteridine reductase; Heat shock protein 90 N-terminal domain; Hippo-pathway; 14-3-3; bioinorganic chemistry; ferritin; glutaminyl cyclase
Special Issues, Collections and Topics in MDPI journals
Interests: structural biology; X-ray crystallography; inorganic chemistry; cancer research; parasitic diseases; neurological disorders; β-lactamases; antibiotic resistance; pteridine reductase; heat shock protein 90; 14-3-3; bioinorganic chemistry; glutaminyl cyclase; bile acid binding protein
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is focused on β-lactamases and, more specifically, on the prominent advances made in recent years on the development of molecules able to effectively block the activity of these enzymes to fight bacteria resistance to β-lactam antibiotics.
In bacteria, a major resistance mechanism to β-lactam antibiotics is the production of one or more β-lactamases. These enzymes are classified in two structurally and mechanistically unrelated families, serine-β-lactamases (SBLs; classes A, C, and D) and the metallo-β-lactamases (MBLs; class B). The interest in discovering novel inhibitors has recently been renewed to counter the threat from extended-spectrum β-lactamases (ESBLs) and carbapenemases which are not inhibited by the classical SBL inhibitors clavulanic acid and tazobactam. Recently, two novel BL inhibitors, the diazabicyclooctane (DBO) avibactam and the boronate vaborbactam, have been reported and are currently applied in clinic in combination with ceftazidime and meropenem, respectively. β-lactamases are a wide family of enzymes, thus, the development of effective pan-class inhibitors is particularly challenging.
This Special Issue features multidisciplinary research focused on serine and metallo-β-lactamases, aiming to provide novel insight on these key targets to counteract bacteria resistance to β-lactam antibiotics. The main topics covered by this Special Issue are the identification and characterization of BL enzymes, mechanistic and structural studies, and the identification and development of SBL and MBL inhibitors.
Dr. Cecilia Pozzi
Dr. Giusy Tassone
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- serine-β-lactamases
- metallo-β-lactamases
- resistance
- β-lactam antibiotics
- β-lactamase inhibitors
- extended spectrum β-lactamases
- carbapenemases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
